[
  {
    "ts": "2026-02-06T09:27:27+00:00",
    "headline": "Bristol Myers Squibb Q4 Earnings Call Highlights",
    "summary": "Bristol Myers Squibb (NYSE:BMY) executives emphasized “focused execution” in 2025 and pointed to continued momentum entering 2026, as the company’s growth portfolio increasingly offsets declines in legacy products. On the company’s fourth-quarter earnings call, management highlighted strong contribu",
    "url": "https://www.marketbeat.com/instant-alerts/bristol-myers-squibb-q4-earnings-call-highlights-2026-02-06/?utm_source=yahoofinance&utm_medium=yahoofinance",
    "source": "MarketBeat",
    "provider": "yfinance",
    "raw": {
      "id": "8fd1a664-c958-3a66-9e34-53496d71ee02",
      "content": {
        "id": "8fd1a664-c958-3a66-9e34-53496d71ee02",
        "contentType": "STORY",
        "title": "Bristol Myers Squibb Q4 Earnings Call Highlights",
        "description": "",
        "summary": "Bristol Myers Squibb (NYSE:BMY) executives emphasized “focused execution” in 2025 and pointed to continued momentum entering 2026, as the company’s growth portfolio increasingly offsets declines in legacy products. On the company’s fourth-quarter earnings call, management highlighted strong contribu",
        "pubDate": "2026-02-06T09:27:27Z",
        "displayTime": "2026-02-06T09:27:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/marketbeat_955/1cac176a25404fffed540f41c3fa51ba",
          "originalWidth": 1200,
          "originalHeight": 675,
          "caption": "Bristol Myers Squibb logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/f2.uIphOWxsUTm0.N3FhpA--~B/aD02NzU7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/marketbeat_955/1cac176a25404fffed540f41c3fa51ba.cf.webp",
              "width": 1200,
              "height": 675,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qiYtjA6hs4ktdAsyJjRpng--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/marketbeat_955/1cac176a25404fffed540f41c3fa51ba.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MarketBeat",
          "url": "https://www.marketbeat.com/"
        },
        "canonicalUrl": {
          "url": "https://www.marketbeat.com/instant-alerts/bristol-myers-squibb-q4-earnings-call-highlights-2026-02-06/?utm_source=yahoofinance&utm_medium=yahoofinance",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bristol-myers-squibb-q4-earnings-092727558.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-06T05:34:48+00:00",
    "headline": "BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus",
    "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue guidance of $46.75 billion at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $1.26 per share was 4.6% above analysts’ consensus estimates.",
    "url": "https://finance.yahoo.com/news/bmy-q4-deep-dive-growth-053448497.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "3ee77ae5-74db-351d-9de9-e014d58f0543",
      "content": {
        "id": "3ee77ae5-74db-351d-9de9-e014d58f0543",
        "contentType": "STORY",
        "title": "BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus",
        "description": "",
        "summary": "Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 1.4% year on year to $12.5 billion. The company’s full-year revenue guidance of $46.75 billion at the midpoint came in 5.7% above analysts’ estimates. Its non-GAAP profit of $1.26 per share was 4.6% above analysts’ consensus estimates.",
        "pubDate": "2026-02-06T05:34:48Z",
        "displayTime": "2026-02-06T05:34:48Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "BMY Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Gk.7_kJOBQAPS7VxEfLOgw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/YM1F85oh4xO4w1Qalh6PGw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/37b3541337ce2b08e582bdc742879f1c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/bmy-q4-deep-dive-growth-053448497.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bmy-q4-deep-dive-growth-053448497.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-06T11:48:23+00:00",
    "headline": "BMS reports flat revenue growth for full-year 2025",
    "summary": "The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.",
    "url": "https://www.pharmaceutical-technology.com/news/bms-flat-revenue-growth-2025/",
    "source": "Pharmaceutical Technology",
    "provider": "yfinance",
    "raw": {
      "id": "d769cfd6-5587-349b-8909-d86f6fcb7062",
      "content": {
        "id": "d769cfd6-5587-349b-8909-d86f6fcb7062",
        "contentType": "STORY",
        "title": "BMS reports flat revenue growth for full-year 2025",
        "description": "",
        "summary": "The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.",
        "pubDate": "2026-02-06T11:48:23Z",
        "displayTime": "2026-02-06T11:48:23Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/pharmaceutical_technology_376/8cd237b2c3b929f3645b5fe46cabcdb0",
          "originalWidth": 1440,
          "originalHeight": 810,
          "caption": "BMS achieved non-GAAP EPS of $6.15 for the full year",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1aapEFq84uYCMk7WVQnrXA--~B/aD04MTA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/pharmaceutical_technology_376/8cd237b2c3b929f3645b5fe46cabcdb0.cf.webp",
              "width": 1440,
              "height": 810,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MOrrcL2Z3omvWvKFgKQvLA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/pharmaceutical_technology_376/8cd237b2c3b929f3645b5fe46cabcdb0.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Pharmaceutical Technology",
          "url": "https://www.globaldata.com/"
        },
        "canonicalUrl": {
          "url": "https://www.pharmaceutical-technology.com/news/bms-flat-revenue-growth-2025/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/bms-reports-flat-revenue-growth-114823162.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-06T12:35:00+00:00",
    "headline": "Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.",
    "summary": "Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.",
    "url": "https://www.barrons.com/articles/biogen-earnings-stock-price-multiple-sclerosis-97907d44?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "2b5e2cbd-cbd1-36b2-8785-d0a519f4ffd7",
      "content": {
        "id": "2b5e2cbd-cbd1-36b2-8785-d0a519f4ffd7",
        "contentType": "STORY",
        "title": "Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.",
        "description": "",
        "summary": "Biogen says it expects revenue to fall in 2026 as its multiple sclerosis therapies continue to struggle.",
        "pubDate": "2026-02-06T12:35:00Z",
        "displayTime": "2026-02-06T12:35:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/2b5e2cbd-cbd1-36b2-8785-d0a519f4ffd7/biogen-stock-rises-even-as.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/8b8d2d22b3ed18c487eedaade240b36a",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kbHZIbt3fMsuwi_ZkVmhkw--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/8b8d2d22b3ed18c487eedaade240b36a.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/nicgyXeo6gfdHNG1tIDKyg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/8b8d2d22b3ed18c487eedaade240b36a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/biogen-earnings-stock-price-multiple-sclerosis-97907d44?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "NVS"
            },
            {
              "symbol": "NVSEF"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-06T15:09:04+00:00",
    "headline": "What Catalysts Are Rewriting The Story For Bristol Myers Squibb (BMY)?",
    "summary": "Recent updates around Bristol Myers Squibb have nudged the fair value estimate to US$58.13 from US$56.26, a modest shift that reflects refreshed assumptions on risk, revenue trends, and how much of the 2026 pipeline potential is being recognized in current pricing. Street research sits in a mixed but generally constructive zone, with some analysts pointing to a busy calendar of upcoming data and others stressing that execution questions and already cautious expectations still matter. Read on...",
    "url": "https://finance.yahoo.com/news/catalysts-rewriting-story-bristol-myers-150904951.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "ad4fe9ca-498b-3f06-9abf-31051f8747c5",
      "content": {
        "id": "ad4fe9ca-498b-3f06-9abf-31051f8747c5",
        "contentType": "STORY",
        "title": "What Catalysts Are Rewriting The Story For Bristol Myers Squibb (BMY)?",
        "description": "",
        "summary": "Recent updates around Bristol Myers Squibb have nudged the fair value estimate to US$58.13 from US$56.26, a modest shift that reflects refreshed assumptions on risk, revenue trends, and how much of the 2026 pipeline potential is being recognized in current pricing. Street research sits in a mixed but generally constructive zone, with some analysts pointing to a busy calendar of upcoming data and others stressing that execution questions and already cautious expectations still matter. Read on...",
        "pubDate": "2026-02-06T15:09:04Z",
        "displayTime": "2026-02-06T15:09:04Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/isv7n73YBii.eJbbdO3fww--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MRv2ZxXw0SbLt6U2idf4TQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5a13d347387951add3c978a1a10a0331.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/catalysts-rewriting-story-bristol-myers-150904951.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/catalysts-rewriting-story-bristol-myers-150904951.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]